Three of Denmark’s most prominent listed companies have erased more than 30% of their market value in the first half of 2026, marking a severe period of underperformance for the C25 index’s heavyweight constituents.
The steep declines at Zealand Pharma, Coloplast, and Ambu highlight a broader retreat by investors from Danish blue chips, even as the wider index attempts to stabilize.
61% rebound in Wednesday’s trading session, the gains were driven by a narrow set of performers rather than broad-based buying interest.
The selloff reflects a shift in sentiment toward domestic equities, with institutional and retail investors alike reducing exposure to these sector leaders.
While the C25 index managed a modest 1.61% rebound in Wednesday’s trading session, the gains were driven by a narrow set of performers rather than broad-based buying interest.
Ambu emerged as the top gainer among index constituents during the session, but the recovery remains fragile against the backdrop of half-year losses that exceed one-third of market capitalization for the three laggards.
This divergence underscores the selective nature of current market flows.